102 related articles for article (PubMed ID: 6279488)
21. Virulence of bluetongue virus for British sheep.
Jeggo MJ; Corteyn AH; Taylor WP; Davidson WL; Gorman BM
Res Vet Sci; 1987 Jan; 42(1):24-8. PubMed ID: 3029846
[TBL] [Abstract][Full Text] [Related]
22. Cross-reactive cytotoxic T cells to serologically distinct vesicular stomatitis virus.
Rosenthal KL; Zinkernagel RM
J Immunol; 1980 May; 124(5):2301-8. PubMed ID: 6154097
[No Abstract] [Full Text] [Related]
23. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
Oura CA; Wood JL; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Floyd T; Simmons H; Batten CA
Vaccine; 2009 Dec; 27(52):7326-30. PubMed ID: 19786141
[TBL] [Abstract][Full Text] [Related]
24. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
[TBL] [Abstract][Full Text] [Related]
25. A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques.
Jeggo MH; Wardley RC; Brownlie J
Immunology; 1984 Jul; 52(3):403-10. PubMed ID: 6086501
[TBL] [Abstract][Full Text] [Related]
26. Immunologic response of sheep to inactivated and virulent bluetongue virus.
Stott JL; Barber TL; Osburn BI
Am J Vet Res; 1985 May; 46(5):1043-9. PubMed ID: 2988376
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep.
Eschbaumer M; Hoffmann B; König P; Teifke JP; Gethmann JM; Conraths FJ; Probst C; Mettenleiter TC; Beer M
Vaccine; 2009 Jun; 27(31):4169-75. PubMed ID: 19406189
[TBL] [Abstract][Full Text] [Related]
28. Bluetongue in cattle: repeated exposure of two immunologically tolerant calves to bluetongue virus by vector bites.
Luedke AJ; Jochim MM; Jones RH
Am J Vet Res; 1977 Nov; 38(11):1701-4. PubMed ID: 201194
[TBL] [Abstract][Full Text] [Related]
29. A study on bluetongue virus infection in Saudi Arabia using sentinel ruminants.
Abu Elzein EM; Aitchison H; al-Afaleq AI; al-Bashir AM; Ibrahim AO; Housawi FM
Onderstepoort J Vet Res; 1998 Dec; 65(4):243-51. PubMed ID: 10192836
[TBL] [Abstract][Full Text] [Related]
30. Cell-mediated immunity in flavivirus infections. I. Induction of cytotoxic T lymphocytes in mice by an attenuated virus from the tick-borne encephalitis complex and its group-reactive character.
Gajdosová E; Oravec C; Mayer V
Acta Virol; 1981 Jan; 25(1):10-8. PubMed ID: 6165230
[TBL] [Abstract][Full Text] [Related]
31. Cross protection among togaviruses in nude mice and littermates.
Latif Z; Gates D; Wust CJ; Brown A
J Gen Virol; 1979 Oct; 45(1):89-98. PubMed ID: 316446
[TBL] [Abstract][Full Text] [Related]
32. Experimental bluetongue infections in gnotobiotic lambs and kids.
Livingston CW; McConnell S; Cummings G; Gauer BB
Am J Vet Res; 1983 Jan; 44(1):129-31. PubMed ID: 6297338
[TBL] [Abstract][Full Text] [Related]
33. A monovalent attenuated serotype 2 bluetongue virus vaccine confers homologous protection in sheep.
Hunter P; Modumo J
Onderstepoort J Vet Res; 2001 Dec; 68(4):331-3. PubMed ID: 12026066
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the humoral response between sheep vaccinated with a killed-virus vaccine and those vaccinated with a modified-live virus vaccine against bluetongue virus serotype 17.
Speiser KL; Schumaker BA; Cook WE; Cornish TE; Cammack KM; Miller MM
J Am Vet Med Assoc; 2016 May; 248(9):1043-9. PubMed ID: 27074613
[TBL] [Abstract][Full Text] [Related]
35. Problems in the interpretation of diagnostic tests due to cross-reactions between orbiviruses and broad serological responses in animals.
Della-Porta AJ; Parsonson IM; McPhee DA
Prog Clin Biol Res; 1985; 178():445-53. PubMed ID: 2989884
[TBL] [Abstract][Full Text] [Related]
36. In vitro neutralization of antigenic variants of bluetongue virus is related to in vivo protection.
Sundin DR; Dean VC; DuBard KM; Mecham JO
Viral Immunol; 1989; 2(3):195-203. PubMed ID: 2560915
[TBL] [Abstract][Full Text] [Related]
37. Potency and efficacy of inactivated bluetongue virus vaccines.
Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic T-cell and antibody responses to influenza infection of mice.
Wells MA; Ennis FA; Daniel S
J Gen Virol; 1979 Jun; 43(3):685-90. PubMed ID: 314495
[TBL] [Abstract][Full Text] [Related]
39. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice.
Webster RG; Askonas BA
Eur J Immunol; 1980 May; 10(5):396-401. PubMed ID: 6967815
[TBL] [Abstract][Full Text] [Related]
40. Why German farmers have their animals vaccinated against Bluetongue virus serotype 8: results of a questionnaire survey.
Gethmann J; Zilow V; Probst C; Elbers AR; Conraths FJ
Vaccine; 2015 Jan; 33(1):214-21. PubMed ID: 25454856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
